(Q43689056)

25 November 2017

title

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects (English)

1 reference

25 November 2017

1 reference

T Sakai

1

1 reference

25 November 2017

N Aoyama

2

1 reference

25 November 2017

T Kita

3

1 reference

25 November 2017

T Sakaeda

4

1 reference

25 November 2017

K Nishiguchi

5

1 reference

25 November 2017

Y Nishitora

6

1 reference

25 November 2017

T Hohda

7

1 reference

25 November 2017

D Sirasaka

8

1 reference

25 November 2017

T Tamura

9

1 reference

25 November 2017

Y Tanigawara

10

1 reference

25 November 2017

M Kasuga

11

1 reference

25 November 2017

K Okumura

12

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Pharmaceutical Research

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

721-727

1 reference

Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma.

25 November 2017

cites work

1 reference

12 December 2020

Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation

1 reference

12 December 2020

Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column

1 reference

12 December 2020

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori

1 reference

12 December 2020

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

12 December 2020

Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori

1 reference

12 December 2020

Biochemistry and molecular biology of the human CYP2C subfamily

1 reference

12 December 2020

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

1 reference

12 December 2020

Oxidative metabolism of lansoprazole by human liver cytochromes P450.

1 reference

12 December 2020

Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers

1 reference

12 December 2020

High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine

1 reference

12 December 2020

Review article: drug interactions with agents used to treat acid-related diseases

1 reference

12 December 2020

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects

1 reference

12 December 2020

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status

1 reference

12 December 2020

Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

Nomenclature for N-acetyltransferases

1 reference

12 December 2020

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

12 December 2020

The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study

1 reference

12 December 2020

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

1 reference

12 December 2020

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

1 reference

12 December 2020

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

1 reference

12 December 2020

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status

1 reference

12 December 2020

Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists.

1 reference

12 December 2020

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

1 reference

12 December 2020

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

12 December 2020

Helicobacter pylori and peptic ulcer disease

1 reference

12 December 2020

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

1 reference

12 December 2020

Helicobacter pylori infection and the risk of gastric carcinoma

1 reference

12 December 2020

NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease

1 reference

12 December 2020

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography

1 reference

12 December 2020

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

12 December 2020

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011035007591

1 reference

25 November 2017

1 reference